Repeat Stereotactic Radiosurgery for Progressive or Recurrent Vestibular Schwannomas.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 20 02 2018
accepted: 07 08 2018
pubmed: 7 9 2018
medline: 26 3 2020
entrez: 7 9 2018
Statut: ppublish

Résumé

Stereotactic radiosurgery (SRS) is a highly effective management approach for patients with vestibular schwannomas (VS), with 10-yr control rates up 98%. When it fails, however, few data are available to guide management. To perform a retrospective analysis of patients who underwent 2 SRS procedures on the same VS to assess the safety and efficacy of this practice. This study was opened to centers of the International Gamma Knife Research Foundation (IGKRF). Data collected included patient characteristics, clinical symptoms at the time of SRS, radiosurgery dosimetric data, imaging response, clinical evolution, and survival. Actuarial analyses of tumor responses were performed. Seventy-six patients from 8 IGKRF centers were identified. Median follow-up from the second SRS was 51.7 mo. Progression after the first SRS occurred at a median of 43 mo. Repeat SRS was performed using a median dose of 12 Gy. Actuarial tumor control rates at 2, 5, and 10 yr following the second SRS were 98.6%, 92.2%, and 92.2%, respectively. Useful hearing was present in 30%, 8%, and 5% of patients at first SRS, second SRS, and last follow-up, respectively. Seventy-five percent of patients reported stable or improved symptoms following the second SRS. Worsening of facial nerve function attributable to SRS occurred in 7% of cases. There were no reports of radionecrosis, radiation-associated edema requiring corticosteroids, radiation-related neoplasia, or death attributable to the repeat SRS procedure. Patients with progressing VS after radiosurgery can be safely and effectively managed using a second SRS procedure.

Sections du résumé

BACKGROUND
Stereotactic radiosurgery (SRS) is a highly effective management approach for patients with vestibular schwannomas (VS), with 10-yr control rates up 98%. When it fails, however, few data are available to guide management.
OBJECTIVE
To perform a retrospective analysis of patients who underwent 2 SRS procedures on the same VS to assess the safety and efficacy of this practice.
METHODS
This study was opened to centers of the International Gamma Knife Research Foundation (IGKRF). Data collected included patient characteristics, clinical symptoms at the time of SRS, radiosurgery dosimetric data, imaging response, clinical evolution, and survival. Actuarial analyses of tumor responses were performed.
RESULTS
Seventy-six patients from 8 IGKRF centers were identified. Median follow-up from the second SRS was 51.7 mo. Progression after the first SRS occurred at a median of 43 mo. Repeat SRS was performed using a median dose of 12 Gy. Actuarial tumor control rates at 2, 5, and 10 yr following the second SRS were 98.6%, 92.2%, and 92.2%, respectively. Useful hearing was present in 30%, 8%, and 5% of patients at first SRS, second SRS, and last follow-up, respectively. Seventy-five percent of patients reported stable or improved symptoms following the second SRS. Worsening of facial nerve function attributable to SRS occurred in 7% of cases. There were no reports of radionecrosis, radiation-associated edema requiring corticosteroids, radiation-related neoplasia, or death attributable to the repeat SRS procedure.
CONCLUSION
Patients with progressing VS after radiosurgery can be safely and effectively managed using a second SRS procedure.

Identifiants

pubmed: 30189018
pii: 5090738
doi: 10.1093/neuros/nyy416
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

535-542

Informations de copyright

Copyright © 2018 by the Congress of Neurological Surgeons.

Auteurs

Christian Iorio-Morin (C)

Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.

Roman Liscak (R)

Na Homolce Hospital, Prague, Czech Republic.

Vilibald Vladyka (V)

Na Homolce Hospital, Prague, Czech Republic.

Hideyuki Kano (H)

Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Rachel C Jacobs (RC)

Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

L Dade Lunsford (LD)

Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Or Cohen-Inbar (O)

Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.

Jason Sheehan (J)

Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.

Reem Emad (R)

National Cancer Institute, Cairo University, Gamma Knife Center Cairo, Cairo, Egypt.

Khalid Abdel Karim (KA)

Clinical Oncology Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.

Amr El-Shehaby (A)

Neurosurgery Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.

Wael A Reda (WA)

Neurosurgery Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.

Cheng-Chia Lee (CC)

Taipei Veterans General Hospital Neurological Institute, Taipei, Taiwan.

Fu-Yuan Pai (FY)

Taipei Veterans General Hospital Neurological Institute, Taipei, Taiwan.

Amparo Wolf (A)

New York University Langone Medical Center, New York, New York.

Douglas Kondziolka (D)

New York University Langone Medical Center, New York, New York.

Inga Grills (I)

Beaumont Gamma Knife Center, Royal Oak, Michigan.

Kuei C Lee (KC)

Beaumont Gamma Knife Center, Royal Oak, Michigan.

David Mathieu (D)

Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH